Drug Pricing Reform Twists And Turns In The COVID-19 Era
Source: Life Science Leader
By Frank Zhou, Sonia Khurana, & Julia Gaebler, Ph.D.
In late 2019, there was strong political momentum toward drug pricing reform, with an expectation of legislation in the first few months of 2020. In an uncommon display of bipartisanship, both the House and the Senate had drafted or passed relevant legislation with significant common ground.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more